Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

On Appetite and Its Loss
Jatoi, Aminah , Kumar, Shaji , Sloan, Jeff A. , Nguyen, Phuong

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 15 | Pages: 2930-2932

10.1200/jco.2000.18.15.2930 | PMID 10920143 Get It

Gastrointestinal: Recurrent urothelial cancer of the remnant ureter invading the ileal conduit: PET/CT imaging
Hafertepe, Michael, Nguyen, Ba D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 21, 2017 | Volume: 32 | Issue: 2 | Pages: 291-291

10.1111/jgh.13483 | PMID 28221692 Get It

Positron emission tomography/computed tomography imaging of adrenocorticotropic hormone-producing small-cell neuroendocrine carcinoma of the cervix
Nguyen, Vien X., Lam‐Himlin, Dora , Nguyen, Ba D. , Lam-Himlin, Dora M

Mayo Clinic

International Journal of Gynecology & Obstetrics | January 20, 2017 | Volume: 137 | Issue: 2 | Pages: 197-198

10.1002/ijgo.12104 | PMID 28106911 Get It

Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer’s Disease Genes in African Americans Identifies Novel PSEN Variants
N’Songo, Aurelie, Carrasquillo, Minerva M. , Wang, Xue , Nguyen, Thuy , Asmann, Yan W. , Younkin, Steven G., Allen, Mariet , Duara, Ranjan , Custo, María T. Greig, Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Asmann, Yan, Carrasquillo, Minerva M. , Duara, Ranjan

Mayo Clinic

Journal of Alzheimer’s Disease | January 20, 2017 | Volume: 56 | Issue: 4 | Pages: 1215-1222

10.3233/jad-161185 | PMID 28106563 Get It

We conducted a comprehensive screening of rare coding variants in an African American cohort to identify novel pathogenic mutations within the early-onset Alzheimer’s disease (EOAD) genes ( APP, PSEN1 , and PSEN2) in this understudied population. Whole-exome sequencing of 238 African American subjects identified 6 rare missense variants within the EOAD genes, which were observed in AD cases but never among controls. These variants were analyzed in an independent cohort of 300 African American subjects in which PSEN2 :NM_000447:exon5:c.T331C:p.Phe111Leu and PSEN1-minilin rs777923890 variants were again not observed, indicating that these novel rare variants, may contribute to AD risk in this population.
ICONE: An International Consortium of Neuro Endovascular Centres
Raymond, Jean , Kallmes, David F. , Spears, Julian , Marotta, Thomas R. , Guilbert, F , Weill, Alain , Molyneux, Andy, Cloft, Harry J. , Çekirge, S., Saatçi, Işıl , Méder, Jean-François , Moret, J. , Cognard, Christophe , Turk, Aquilla S , Berenstein, Alejandro , White, Phil , Roy, Daniel C. , Nguyen, Thanh N. , Çekirge, Saruhan , Bracard, Serge , Qureshi, Adnan Iqbal , Cognard, Christophe

Mayo Clinic

Interventional Neuroradiology | January 11, 2017 | Volume: 14 | Issue: 2 | Pages: 203-208

10.1177/159101990801400213 | PMID 20557763 Get It

The proliferation of new endovascular devices and therapeutic strategies calls for a prudent and rational evaluation of their clinical benefit. This evaluation must be done in an effective manner and in collaboration with industry. Such research initiative requires organisational and methodological support to survive and thrive in a competitive environment. We propose the formation of an international consortium, an academic alliance committed to the pursuit of effective neurovascular therapies. Such a consortium would be dedicated to the design and execution of basic science, device development and clinical trials. The Consortium is owned and operated by its members. Members are international leaders in neurointerventional research and clinical practice. The Consortium brings competency, knowledge, and expertise to industry as well as to its membership across a spectrum of research initiatives such as: expedited review of clinical trials, protocol development, surveys and systematic reviews; laboratory expertise and support for research design and grant applications to public agencies. Once objectives and protocols are approved, the Consortium provides a stable network of centers capable of timely realization of clinical trials or preclinical investigations in an optimal environment. The Consortium is a non-profit organization. The potential revenue generated from client-sponsored financial agreements will be re-directed to the academic and research objectives of the organization. The Consortium wishes to work in concert with industry, to support emerging trends in neurovascular therapeutic development. The Consortium is a realistic endeavour optimally structured to promote excellence through scientific appraisal of our treatments, and to accelerate technical progress while maximizing patients' safety and welfare.
Role Development of Nurse Practitioners and Physician Assistants in Liver Transplantation
Chaney, Amanda , Harnois, Denise M. , Musto, Kaitlyn R., Nguyen, Justin H. , Chaney, Amanda J

Mayo Clinic

Progress in Transplantation | January 10, 2017 | Volume: 26 | Issue: 1 | Pages: 75-81

10.1177/1526924816632116 | PMID 27136253 Get It

Background: Nurse practitioners (NPs) and physician assistants (PAs) are increasingly utilized in health care. However, their roles in liver transplantation (LT) have not been investigated. Materials and Methods: In this study, we reviewed the employment and development of NPs and PAs and their impact on our deceased-donor LT (DDLT) program. Results: We found a safe and efficient way to utilize NPs and PAs in a DDLT program. Since the beginning of our program, Model of End-Stage Liver Disease (MELD) scores have increased significantly, suggesting patients are sicker at the time of transplant, and wait times of patients have become longer. With the incorporation of NPs and PAs, we found that length of stay (LOS) was not affected. The overall median warm ischemic time did not increase. Outcomes of LT for both patient and graft survival actually improved and remain at or above the expected values. These results collectively support the usefulness and validity of NPs and PAs in a DDLT program. Conclusion: We have determined that surgical and medical NPs and PAs are essential for optimal patient outcomes. They facilitate a better learning experience for residents and fellows on their transplant rotations. Further investigations to assess the roles of these providers and their impact on the education of residents and fellows in transplantation are warranted. Further transplant hepatology education programs and/or fellowships are recommended to assist in the education and professional development of transplant NPs and PAs.
Diabetic and idiopathic gastroparesis is associated with loss of CD206‐positive macrophages in the gastric antrum
Grover, M., Bernard, C, Pasricha, Pankaj J. , Tonascia, James , Koch, Kenneth L. , McCallum, Richard W. , Sarosiek, Irene , Snape, William J., Kendrick, Michael L. , Kellogg, Todd A., McKenzie, Travis J. , Hamilton, Frank A., Farrugia, Gianrico , Parkman, Henry P. , Gibbons, Simon J. , Hasler, William L. , Nguyen, Linda Anh B. , Abell, Thomas L.

Mayo Clinic

Neurogastroenterology & Motility | January 9, 2017 | Volume: 29 | Issue: 6 | Pages: No page available

10.1111/nmo.13018 | PMID 28066953 Get It

AbstractBackgroundAnimal studies have increasingly highlighted the role of macrophages in the development of delayed gastric emptying. However, their role in the pathophysiology of human gastroparesis is unclear. Our aim was to determine changes in macrophages and other cell types in the gastric antrum muscularis propria of patients with diabetic and idiopathic gastroparesis.MethodsFull thickness gastric antrum biopsies were obtained from patients enrolled in the Gastroparesis Clinical Research Consortium (11 diabetic, 6 idiopathic) and 5 controls. Immunolabeling and quantitative assessment was done for interstitial cells of Cajal (ICC) (Kit), enteric nerves protein gene product 9.5, neuronal nitric oxide synthase, vasoactive intestinal peptide, substance P, tyrosine hydroxylase), overall immune cells (CD45) and anti‐inflammatory macrophages (CD206). Gastric emptying was assessed using nuclear medicine scintigraphy and symptom severity using the Gastroparesis Cardinal Symptom Index.ResultsBoth diabetic and idiopathic gastroparesis patients showed loss of ICC as compared to controls (Mean [standard error of mean]/hpf: diabetic, 2.28 [0.16]; idiopathic, 2.53 [0.47]; controls, 6.05 [0.62]; P=.004). Overall immune cell population (CD45) was unchanged but there was a loss of anti‐inflammatory macrophages (CD206) in circular muscle (diabetic, 3.87 [0.32]; idiopathic, 4.16 [0.52]; controls, 6.59 [1.09]; P=.04) and myenteric plexus (diabetic, 3.83 [0.27]; idiopathic, 3.59 [0.68]; controls, 7.46 [0.51]; P=.004). There was correlation between the number of ICC and CD206‐positive cells (r=.55, P=.008). Enteric nerves (PGP9.5) were unchanged: diabetic, 33.64 (3.45); idiopathic, 41.26 (6.40); controls, 46.80 (6.04).ConclusionLoss of antral CD206‐positive anti‐inflammatory macrophages is a key feature in human gastroparesis and it is associates with ICC loss.
Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell–like spheroids, and tumor xenografts through multiple cell signaling pathways
Bijangi‐Vishehsaraei, Khadijeh , Saadatzadeh, M. Reza , Nguyen, Angie, Kamocka, Malgorzata M. , Cai, Wenjing , Cohen‐Gadol, Aaron , Halum, Stacey L. , Pollok, Karen E. , Safa, Ahmad R., Wang, Haiyan , Cai, Wenjing, Sarkaria, Jann N.

Mayo Clinic

Journal of Neurosurgery | January 6, 2017 | Volume: 127 | Issue: 6 | Pages: 1219-1230

10.3171/2016.8.jns161197 | PMID 28059653 Get It

OBJECTIVE Defects in the apoptotic machinery and augmented survival signals contribute to drug resistance in glioblastoma (GBM). Moreover, another complexity related to GBM treatment is the concept that GBM development and recurrence may arise from the expression of GBM stem cells (GSCs). Therefore, the use of a multifaceted approach or multitargeted agents that affect specific tumor cell characteristics will likely be necessary to successfully eradicate GBM. The objective of this study was to investigate the usefulness of sulforaphane (SFN)—a constituent of cruciferous vegetables with a multitargeted effect—as a therapeutic agent for GBM. METHODS The inhibitory effects of SFN on established cell lines, early primary cultures, CD133-positive GSCs, GSC-derived spheroids, and GBM xenografts were evaluated using various methods, including GSC isolation and the sphere-forming assay, analysis of reactive oxygen species (ROS) and apoptosis, cell growth inhibition assay, comet assays for assessing SFN-triggered DNA damage, confocal microscopy, Western blot analysis, and the determination of in vivo efficacy as assessed in human GBM xenograft models. RESULTS SFN triggered the significant inhibition of cell survival and induced apoptotic cell death, which was associated with caspase 3 and caspase 7 activation. Moreover, SFN triggered the formation of mitochondrial ROS, and SFN-triggered cell death was ROS dependent. Comet assays revealed that SFN increased single- and double-strand DNA breaks in GBM. Compared with the vehicle control cells, a significantly higher amount of γ-H2AX foci correlated with an increase in DNA double-strand breaks in the SFN-treated samples. Furthermore, SFN robustly inhibited the growth of GBM cell–induced cell death in established cell cultures and early-passage primary cultures and, most importantly, was effective in eliminating GSCs, which play a major role in drug resistance and disease recurrence. In vivo studies revealed that SFN administration at 100 mg/kg for 5-day cycles repeated for 3 weeks significantly decreased the growth of ectopic xenografts that were established from the early passage of primary cultures of GBM10. CONCLUSIONS These results suggest that SFN is a potent anti-GBM agent that targets several apoptosis and cell survival pathways and further preclinical and clinical studies may prove that SFN alone or in combination with other therapies may be potentially useful for GBM therapy.
ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
McLaughlin, Patrick W. , Liss, Adam L., Nguyen, Paul L. , Assimos, Dean G. , D’Amico, Anthony V. , Gustafson, Gary, Keole, Sameer R., Liauw, Stanley L. , Movsas, Benjamin , Prestidge, Bradley R., Showalter, Timothy N. , Taira, Al V., Vapiwala, Neha , GOTTSCHALK, ALEXANDER R. , Lloyd, Shane , Davis, Brian J. , Liauw, Stanley L

Mayo Clinic

American Journal of Clinical Oncology | January 6, 2017 | Volume: 40 | Issue: 1 | Pages: 1-10

10.1097/coc.0000000000000354 | PMID 28059930 Get It

Purpose: To present the most updated American College of Radiology consensus guidelines formed from an expert panel on treatment of locally advanced, high-risk prostate cancer Methods: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. Results: The panel summarized the most recent and relevant literature on the topic and voted on 4 clinical variants illustrating the appropriate management of locally advanced, high-risk cancer. Numerical rating and commentary reflecting the panel consensus was given for each treatment approach in each variant. Conclusions: Aggressive local approaches including surgery followed by adjuvant XRT, beam combined with androgen deprivation therapy, and beam combined with brachytherapy have resulted in unpresented success in locally advanced, high-risk prostate cancer. By combining most recent medical literature and expert opinion, this guideline can aid clinicians in the appropriate integration of available therapeutic modalities.